Eric Easom
Chief Executive Officer · AN2 Therapeutics, Inc.
- 2024
- Mar 23, 2026
- 3
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Eric Easom files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Robin Shane Readnour - $317K in ANTX purchases and sales in the last 12 months
- Joshua M. Eizen - $53K in ANTX purchases and sales in the last 12 months
- Margaret M. Fitzpatrick - $12K in ANTX purchases and sales in the last 12 months
- Sanjay Chanda - $9K in ANTX purchases and sales in the last 12 months
- Lucy Day - $9K in ANTX purchases and sales in the last 12 months
- Stephen David Prior - $7K in ANTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Eric Easom?
Eric Easom is a corporate insider, tracked as Chief Executive Officer of AN2 Therapeutics, Inc. (ANTX). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Eric Easom last file a Form 4?
The most recent primary Form 4 on record is dated 23 March 2026, one of 3 filings going back to 2024.
Has Eric Easom been buying or selling stock?
Recorded transactions: 1 open-market purchase ($50K) and 0 open-market sales across all tracked filings.
